Marinomed Biotech AG is a biopharmaceutical company focused on inventing, developing, and partnering clinically meaningful therapies for patients suffering from serious viral infectious diseases and autoreactive immune disorders. Since its foundation in 2006, Marinomed has launched two powerful technologies (Carragelose® and Marinosolv®) with promising product candidates in the pipeline and a great potential for
developing drugs that target diseases with high unmet medical need.
R&D:Marinomed has a track record of success with products based on Carragelose already marketed intemationally and several follow-on compounds in development. The patent-protected Marinosolv® technology enables novel stable aqueous formulations of hardly soluble compounds such as but not limited to corticosteroids, allowing a faster onset of action and better bioavailabllity. Please contact us for further information or visit www.marinosolv.com. Marinosolv® might solve your drug formulation problem.
Production:Marinomed has outsourced production and manufacturing to first class renowned partners. All Carragelose® containing products are part of a viurs-blocking OTC product portfolio targeting common cold and flu-like illnesses and treat viral infections of the respiratory tract including SARS-CoV-2 and its variants. The products are launched in several European as well as non-European countries. Details at: https://www.carragelose.com/en/portfolio/launched-products
Services:Marinomed offers Solv4U technology partnerships based on its patented-protected Marinosolv® technology to support pharmaceutical companies in formulation development for hydrophobic small-molecule active pharmaceutical ingredients (APIs) in all stages of drug discovery. More information on Solv4U: https://www.solv4u.com/en
Sales/Distribution:Marinomed products are distributed and sold via partnerships with internationally renowned companies. For details visit: https://www.marinomed.com/en/technologies-markets/business-development